banner
HIV integrase inhibitor GS-9137, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ895

HIV integrase inhibitor GS-9137, Purity ≥98%

Synonym: 697761-98-1; HIV integrase inhibitor; GS9137

  • MDL: MFCD11846134
  • CAS Number: 697761-98-1
  • Compound CID: 5277135
img
Product Size
10 mg; 50 mg; 100 mg; 200 mg
Price
Datasheet
MSDS
Properties
Description
GS-9137, soluble in DMSO and ethanol and insoluble in water, blocks the action of the integrase enzyme, which is crucial for the HIV virus to integrate its genetic material into the host cell’s DNA, thereby impeding the virus’s ability to replicate and spread. It targets HIV-1 IIIB, HIV-2 EHO, and HIV-2 ROD.
Molecular Weight
447.9
Molecular Formula
C23H23ClFNO5
Targets
HIV-1 IIIB: 0.7 nM; HIV-2 EHO: 2.8 nM; HIV-2 ROD: 1.4 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 85 mg/mL (189.78 mM); Water: Insoluble; Ethanol: 33 mg/mL (73.67 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
GS-9137 is used to block HIV-1 integrase, critical for viral DNA integration into the host genome, advancing HIV research.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0